Verdant Commits Scientific Expertise to ALS Patient Advocacy

In all of our mortal lives, there will come a day when we will be faced with a malady for which there is no cure. Among the incurable, untreatable, and terminal diseases, we have been particularly touched by our individual experiences with patients suffering from the neurodegenerative condition known as ALS. We believe that we are in a unique position to do more good by committing our scientific, regulatory, and business expertise to the patients themselves.

We believe this because we’ve already been doing it for individuals who are close to us, personally. We’ve used our scientific expertise to cut through the noise and identify the most promising options available, and still in the pipeline. We’ve educated patients and their doctors on possibilities that no one has yet considered – including how to access them. We’ve used our modest lab to conduct preliminary investigations and confirm hypotheses. And we’ve freely collaborated with the organizations who truly want what’s best for patients without regard to our personal benefit.

Advocacy also often requires conflict resolution, and that’s most effective with the kind of teeth a business can wield. We’ve used our legal expertise to lock horns with the FDA over patient rights. We’ve used our business leverage to lean on drug patent holders in order to get better clinical trials underway in more locations. And (when we’ve had to) we’ve used our experience with the pharmaceutical industry to fight every bit as dirty as they do.

In short, patients are passengers in a pharmaceutical engine. We can’t change that about the world, but we can certainly square up the odds in favor of the patients. We’re understand the industry from the inside, and we’re not beholden to anyone in it. Patients just want the therapy that’s truly best for them, and as scientists, we have a responsibility to present them with the best options – not what has the best patent protection, or the most investors. That may paint a target on our back, but small targets are hard to hit, so we’re strangely comfortable with it.

Comments